Veritone, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Financial Instruments - Additional Information (Detail)

Financial Instruments - Additional Information (Detail) - USD ($)				1 Months Ended		3 Months Ended
	Dec. 13, 2023	Mar. 01, 2022	Sep. 14, 2021	Jul. 31, 2023	Sep. 30, 2022	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Nov. 16, 2021
Schedule Of Available For Sale Securities [Line Items]
Common stock, par value						$ 0.001		$ 0.001
Common stock issued						206,957	206,957
Contingent consideration, current						$ 500,000		$ 1,000,000
Sale price of common stock									$ 27.74
Impairment						$ 0
Common stock, shares outstanding						37,629,461		37,186,348
Other Noncurrent Assets [Member] \| Level 2
Schedule Of Available For Sale Securities [Line Items]
Investment at fair value						$ 2,021,000		$ 2,021,000
Other Noncurrent Assets [Member] \| Level 3 [Member]
Schedule Of Available For Sale Securities [Line Items]
Strategic investment						$ 2,750,000		$ 2,750,000
Pandologic Ltd [Member]
Schedule Of Available For Sale Securities [Line Items]
Business acquisition, effective date of acquisition			Sep. 14, 2021
Business acquisition, percentage of ownership interests acquired			100.00%
Business acquisition, name of acquired entity			PandoLogic, Ltd. (“PandoLogic”)
Business acquisition, date of acquisition agreement			Jul. 21, 2021
March 2022 Acquisition [Member]
Schedule Of Available For Sale Securities [Line Items]
Contingent compensation				$ 3,500,000
Business acquisition, effective date of acquisition		Mar. 01, 2022
Business acquisition, percentage of ownership interests acquired		100.00%
Stock Consideration [Member] \| PandoLogic Merger Agreement [Member]
Schedule Of Available For Sale Securities [Line Items]
Sale price of common stock								$ 20.53
Term Loan Facility [Member] \| Lenders [Member]
Schedule Of Available For Sale Securities [Line Items]
Shares of common stock purchased for issuance of warrants						2,658,883
Common stock, par value	$ 0.001
Warrants net settled						349,657
Common stock issued						206,957
Minimum [Member]
Schedule Of Available For Sale Securities [Line Items]
Contingent consideration					$ 10,825,000
Minimum [Member] \| Term Loan Facility [Member] \| Lenders [Member]
Schedule Of Available For Sale Securities [Line Items]
Shares of common stock purchased for issuance of warrants	3,008,540
Maximum [Member] \| Pandologic Ltd [Member]
Schedule Of Available For Sale Securities [Line Items]
Contingent consideration, current			$ 65,000,000
Maximum [Member] \| March 2022 Acquisition [Member]
Schedule Of Available For Sale Securities [Line Items]
Contingent consideration		$ 4,500,000